Skip to main content
2025 National Biotechnology Conference Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

TRACK 1: Inspiring Innovation in Formulation, Bioprocessing, and Drug Delivery

Category: Poster Abstract

(T0930-01-02) Investigating the Effects of Multi-Drug-Loaded Nanospheres in Enhancing Antitumor Efficacy and Augmenting Immune Response Against Metastatic Melanoma

Tuesday, May 6, 2025
9:30 AM – 10:30 AM ET


Purpose: Melanoma, the deadliest form of skin cancer, primarily metastasizes through the lymphatic system, and the small molecules used for treatment do not reach therapeutic concentrations lymphatically.

Methods: Here, we develop drug-loaded nanoparticles designed for preferential lymphatic uptake to more effectively treat melanoma in the lymphatic system compared to orally administered small molecules in a clinically relevant transgenic mouse model.

Results: Multi-drug nanoparticles had high in vitro efficacy and synergy, a maximum tolerated dose in mice was established with once-weekly subcutaneous dosing, and nanoparticles demonstrated higher efficacy against lymphatic metastases in a transgenic mouse model compared to orally administered medications. Efficacy was especially pronounced in a sentinel lymph node. Nanoparticles were also able to increase systemic anti-tumor response.

Conclusion: This work indicates that developing nanoparticle-based drug delivery platforms for the treatment of lymphatically metastasizing melanoma may be a viable therapeutic option with the potential for clinical development.

Nanoparticles stability and characterization DT-NP: Debrafenib and Trametinib loaded nanoparticles. DTP-NP Debrafenib, Trametinib, and Pictilisib loaded nanoparticles

Effects of lymph node targeted two-drug and three-drug combination on metastasis of melanoma to Proximal lymph node and Spleen. DT-NP: Debrafenib and Trametinib loaded nanoparticles. DTP-NP Debrafenib, Trametinib, and Pictilisib loaded nanoparticles, P-NP: Pictilisib only nanoparticle, DT-S: Debrafenib, and Trametinib suspension.


Effects of lymph node targeted two-drug and three-drug combination on immune cell population in Spleen.
DT-NP: Debrafenib and Trametinib loaded nanoparticles. DTP-NP Debrafenib, Trametinib, and Pictilisib loaded nanoparticles, DT-S: Debrafenib, and Trametinib suspension.